Literature DB >> 25596811

Vitiligo.

Khaled Ezzedine1, Viktoria Eleftheriadou2, Maxine Whitton2, Nanja van Geel3.   

Abstract

Vitiligo, an acquired pigmentary disorder of unknown origin, is the most frequent cause of depigmentation worldwide, with an estimated prevalence of 1%. The disorder can be psychologically devastating and stigmatising, especially in dark skinned individuals. Vitiligo is clinically characterised by the development of white macules due to the loss of functioning melanocytes in the skin or hair, or both. Two forms of the disease are well recognised: segmental and non-segmental vitiligo (the commonest form). To distinguish between these two forms is of prime importance because therapeutic options and prognosis are quite different. The importance of early treatment and understanding of the profound psychosocial effect of vitiligo will be emphasised throughout this Seminar.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25596811     DOI: 10.1016/S0140-6736(14)60763-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  154 in total

1.  Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Ann Transl Med       Date:  2015-12

2.  Localised hypopigmentation: clarification of a diagnostic conundrum.

Authors:  Shirley Poon; Renée A Beach
Journal:  Br J Gen Pract       Date:  2018-09       Impact factor: 5.386

Review 3.  Vitiligo Pathogenesis and Emerging Treatments.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

4.  MicroRNA-211 Regulates Oxidative Phosphorylation and Energy Metabolism in Human Vitiligo.

Authors:  Anupama Sahoo; Bongyong Lee; Katia Boniface; Julien Seneschal; Sanjaya K Sahoo; Tatsuya Seki; Chunyan Wang; Soumen Das; Xianlin Han; Michael Steppie; Sudipta Seal; Alain Taieb; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2017-05-11       Impact factor: 8.551

Review 5.  Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Authors:  Elisabeth I Minder; Jasmin Barman-Aksoezen; Xiaoye Schneider-Yin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.

Authors:  Narges K Tafreshi; Christopher J Tichacek; Darpan N Pandya; Michael L Doligalski; Mikalai M Budzevich; HyunJoo Kil; Nikunj B Bhatt; Nancy D Kock; Jane L Messina; Epifanio E Ruiz; Nella C Delva; Adam Weaver; William R Gibbons; David C Boulware; Nikhil I Khushalani; Ghassan El-Haddad; Pierre L Triozzi; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

7.  The effects of phototherapy and melanocytes on keratinocytes.

Authors:  Luyan Tang; Wenyu Wu; Wenwen Fu; Yao Hu
Journal:  Exp Ther Med       Date:  2018-01-30       Impact factor: 2.447

8.  No Association between Vitiligo and Obesity: A Case-Control Study.

Authors:  Federica Dragoni; Rossana Conti; Simone Cazzaniga; Roberta Colucci; Lisa Pisaneschi; Luigi Naldi; Silvia Moretti
Journal:  Med Princ Pract       Date:  2017-09-12       Impact factor: 1.927

Review 9.  Understanding autoimmunity of vitiligo and alopecia areata.

Authors:  Jillian F Rork; Mehdi Rashighi; John E Harris
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856

Review 10.  [Dermatological diseases and their importance for psychiatry].

Authors:  P Mavrogiorgou; G Juckel
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.